Research suggests that turmeric and its active compound curcumin show modest potential for supporting digestive and liver health, though the evidence as it relates specifically to these outcomes in the studies provided is limited and comes with important caveats. The most directly relevant finding comes from a six-month randomized, double-blind, placebo-controlled trial in which a liquid formula containing turmeric alongside other botanical ingredients was associated with significant improvements in liver enzyme markers compared to placebo, though the multi-ingredient nature of the formula makes it difficult to attribute any benefit specifically to turmeric alone. Several other studies in this collection touch on turmeric only incidentally — as part of broader investigations into spice consumption, traditional medicine use, or COVID-19 outcomes — and do not provide direct evidence about digestive health benefits. Across the available literature, study designs are mixed in quality and relevance, placebo-controlled trials are few, and researchers consistently note limitations such as small sample sizes, combination formulas that obscure individual ingredient effects, and bioavailability challenges that may limit how well curcumin is absorbed and utilized by the body.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Long-Term Safety and Efficacy of a Highly Purified Plant-Based Nutraceutical ... | Other | 2025 | Supports | 67 |
| A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE EFFECT OF CURCUMIN (TURMERIC) ON... | Other | 2023 | Neutral | 62 |
| COVID-19 and Curcumin: Using VOSviewer software to explore scientific landsca... | Other | 2022 | Neutral | 57 |
| Relation of spice consumption with COVID-19 first wave statistics (infection,... | Other | 2022 | Neutral | 52 |
| Plant-based natural products for symptomatic relief of Parkinson’s disease: p... | Other | 2023 | Neutral | 47 |
| AYUSH medicine as add-on therapy for mild category COVID-19; an open label ra... | Other | 2020 | — | 42 |
| Heavy Metals Induced Health Risk Assessment Through Consumption of Selected C... | Other | 2023 | Neutral | 37 |
| Use of medicinal plants for COVID-19 prevention and respiratory symptom treat... | Other | 2021 | Neutral | 32 |
| Use of antimicrobials during the COVID-19 pandemic: a qualitative study among... | Other | 2023 | Neutral | 27 |
| Long Covid: quantitative and qualitative analyses of online Long Haulers’ exp... | Other | 2020 | Neutral | 22 |
| EuroQol-5D-3L in Long Covid patients After Supplementation with EchA Marine<s... | Other | 2023 | Neutral | 17 |
| DrugWAS: Leveraging drug-wide association studies to facilitate drug repurpos... | Other | 2021 | Neutral | 12 |